Johnson & Johnson is poised for growth with a strong oncology and immunology pipeline, including promising drugs like CARVYKTI and TREMFYA showing significant progress. The company reported a 56% stock rally over the past year and raised earnings guidance, expecting to become the top oncology firm by 2030. However, challenges such as declining sales of the blockbuster drug STELARA and rising litigation costs pose risks. Analysts remain optimistic with a $311.49 price target, reflecting a 15.3% upside, but caution that growth depends on managing these headwinds and successful execution of its strategy.
As of Sep 29, 2026 01:11 WIB, Johnson & Johnson shares are trading at USD 272.16 on Pluang, showing a modest 0.35% increase for the day. The company holds a substantial market capitalization of $653.61 billion, reflecting its significant presence in the health sector. Despite strong investor interest, with a typical hold time of 129 days, the majority of Pluang users are currently selling, with 86% of order activity on the platform being sell orders.
Procter & Gamble, Johnson & Johnson, and Coca-Cola have each increased their dividends annually through eight major economic downturns since the 1960s, including stagflation, recessions, and the pandemic. These companies have strong cash flows and so...
AbbVie and Johnson & Johnson are both strong dividend stocks trading near their 52-week highs, but they differ significantly in risk and growth. AbbVie shows faster revenue growth and a higher dividend yield, driven by its immunology drugs, but faces...
Johnson & Johnson announced that its drug Tremfya significantly improved spinal pain and stiffness in adults with axial psoriatic arthritis in a Phase 4 clinical trial. The STAR study showed Tremfya outperformed placebo in reducing disease activity a...
Johnson & Johnson announced that TREMFYA (guselkumab) met primary and major secondary endpoints in the Phase 4 STAR study, showing significant improvement in axial symptoms and MRI-confirmed inflammation in biologic-naïve adults with active psoriatic...
Johnson & Johnson announced long-term results from the Phase 2 CARTITUDE-2 study showing that 50% of multiple myeloma patients treated early with a single CARVYKTI infusion remained alive and progression-free for at least five years without maintenan...
